Mail & Guardian (Johannesburg) - July 12, 2002
She said the only concern she had raised with the reporter was that the government had not been able to establish from the US Food and Drug Administration why the application for registration of nevirapine had been withdrawn in the US.
Treatments priced beyond Africa: Drug companies at the international Aids conference in Barcelona on Tuesday announced progress in developing innovative Aids therapies, but the good news is not meant for Africa. Most of the sophisticated new treatments will be priced out of the reach of developing countries, where 95% of those infected with the virus live.
At about $10 000 to $12 000 a year, some of the more promising drugs will be completely out of the reach of Africans, most of whom live on far less than a dollar a day.
Source: newsday.com, Reuters, Sapa
020712
MG020707
Copyright © 2002 - Daily Mail & Guardian. For information about the content or for permission to redistribute, publish or use for broadcast, contact the publisher.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .